Evidence map›Paper›PMID 35039300›Full record

Trial reportBMJ open2022

Cost-utility analysis of LEGO based therapy for school children and young people with autism spectrum disorder: results from a randomised controlled trial.

Han-I Wang, Barry Debenham Wright, Matthew Bursnall, Cindy Cooper, Ellen Kingsley, Ann Le Couteur, Dawn Teare, Katie Biggs, Kirsty McKendrick, Gina Gomez de la Cuesta and 9 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Improving the Scope of Child Mental Health Interventions in Our Modern World.International journal of environmental research and public health · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Han-I WangDepartment of Health Sciences, University of York, York, North Yorkshire, UK han-i.wang@york.ac.uk.ORCID 0000-0002-3521-993X
Barry Debenham WrightDepartment of Health Sciences, University of York, York, North Yorkshire, UK.
Matthew BursnallClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.
Cindy CooperClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.
Ellen KingsleyCOMIC Research Team, Leeds and York Partnership NHS Foundation Trust, Leeds, UK.
Ann Le CouteurSir James Spence Institute, Newcastle University, Newcastle upon Tyne, UK.
Dawn TearePopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Katie BiggsClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.ORCID 0000-0003-4468-7417
Kirsty McKendrickClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.
Gina Gomez de la CuestaPlay Included a Community Interest Company, Cambridge, UK.
Tim ChaterLiverpool Clinical Trials Centre, University of Liverpool, Liverpool, Merseyside, UK.
Amy BarrClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.
Kiera SolaimanClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.
Anna PackhamClinical Trials Research Unit, ScHARR, The University of Sheffield, Sheffield, UK.
David MarshallCentre for Reviews and Dissemination, University of York, York, North Yorkshire, UK.ORCID 0000-0001-5969-9539
Danielle VarleyDepartment of Health Sciences, University of York, York, North Yorkshire, UK.
Roshanak NekooiCOMIC Research Team, Leeds and York Partnership NHS Foundation Trust, Leeds, UK.
Simon GilbodyDepartment of Health Sciences, University of York, York, North Yorkshire, UK.
Steve ParrottDepartment of Health Sciences, University of York, York, North Yorkshire, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the cost-effectiveness of LEGO-based therapy compared with usual support.

designCost-utility analysis alongside randomised control trial.

settingMainstream primary and secondary schools in the UK.

participants248 children and young people (CYP) with autism spectrum disorder (ASD) aged 7-15 years.

interventionLEGO-based therapy is a group social skills intervention designed specifically for CYP with ASD. Through play, CYP learn to use the skills such as joint attention, sharing, communication and group problem-solving. CYP randomised to the intervention arm received 12 weekly sessions of LEGO-based therapy and usual support, while CYP allocated to control arm received usual support only.

main outcome measuresAverage costs based on National Health Service (NHS) and personal social services perspective and quality-adjusted life years (QALYs) measured by EQ-5D-Y over time horizon of 1 year were collected during the trial. Incremental cost-effectiveness ratio (ICER) was calculated, and non-parametric bootstrapping was conducted. The uncertainty around the ICER estimates was presented using cost-effectiveness acceptability curve (CEAC). A set of sensitivity analyses were conducted to assess the robustness of the primary findings.

resultsAfter adjustment and bootstrapping, on average, CYP in LEGO-based therapy group incurred less costs (incremental cost was -£251 (95% CI -£752 to £268)) and gained marginal improvement in QALYs (QALYs gained 0.009 (95% CI -0.008 to 0.028)). The CEAC shows that the probability of LEGO-based therapy being cost-effective was 94% at the willingness-to-pay threshold of £20 000 per QALY gained. Results of sensitivity analyses were consistent with the primary outcomes.

conclusionCompared with usual support, LEGO-based therapy produced marginal reduction in costs and improvement in QALYs. Results from both primary and sensitivity analyses suggested that LEGO-based therapy was likely to be cost-effective. TRIAL REGISTRATION NUMBER: ISRCTN64852382.

Indexed as

Autism Spectrum DisorderAdolescentChildCost-Benefit AnalysisHumansProblem SolvingQuality-Adjusted Life YearsQuality of LifeState Medicinechild & adolescent psychiatryclinical trialshealth economics

Identifiers

PMID35039300
PMCPMC8765033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.